Pesquisar
NuCana PLC
NCNAAdicionar à lista de desejos
1.590USD
+0.110+7.43%
Fechamento 08-14 16:00（ET）Cotações atrasadas em 15 min
6.85MValor de mercado
0.03P/L TTM
Mais detalhes de NuCana PLC Empresa
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
NuCana PLC Perfil
Código da empresaNCNA
Nome da EmpresaNuCana PLC
Data de listagemSep 28, 2017
CEO- -
Número de funcionários20
Tipo de títulosDepository Receipt
Fim do ano fiscalSep 28
EndereçoLochside House
CidadeEDINBURGH
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalEH12 9DT
Telefone4401313571111
Sitehttps://www.nucana.com/
Código da empresaNCNA
Data de listagemSep 28, 2017
CEO- -
Executivos da empresa NuCana PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
53.00
--
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
53.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
--
Dr. Cyrille Leperlier, M.D.
Dr. Cyrille Leperlier, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Bali Muralidhar, M.D., Ph.D
Dr. Bali Muralidhar, M.D., Ph.D
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Andrew Kay
Mr. Andrew Kay
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Christopher F. Brinzey
Mr. Christopher F. Brinzey
Investor Relations
Investor Relations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
53.00
--
Mr. Hugh S. Griffith
Mr. Hugh S. Griffith
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
53.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
--
Mr. Martin Mellish
Mr. Martin Mellish
Non-Executive Independent Director
Non-Executive Independent Director
7.00
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
4.00
--
Perguntas frequentes
Quem são os cinco principais acionistas de NuCana PLC?
Os cinco principais acionistas de NuCana PLC são: Mr. Hugh S. Griffith
Quantas instituições possuem ações da NuCana PLC (NCNA)?
Em 2026Q1, 46 instituições possuíam ações da NuCana PLC, com valor de mercado aproximado de 32.77K, representando 0.79% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -151989.00.